Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
GLUE | US
-0.38
-1.88%
Healthcare
Biotechnology
30/06/2024
24/04/2026
19.79
20.23
20.45
19.44
Monte Rosa Therapeutics Inc. a clinical-stage biotechnology company engages in the development of novel small molecule precision medicines that employ the body's natural mechanisms to selectively degrade therapeutically relevant proteins. The company develops an orally bioavailable molecular glue degrader for GSPT1 a a translation termination factor for the treatment of Myc-driven cancers. It also develops CDK2 to treat ovarian uterine and breast cancers; NEK7 for the treatment of inflammatory diseases such as gout and Crohn's disease neurodegenerative disease diabetes and liver disease; VAV1 a target protein for autoimmune diseases; and a therapeutically-relevant protein in hemoglobinopathies. The company was incorporated in 2019 and is headquartered in Boston Massachusetts.
View LessPositive Momentum
Low Debt to Equity (< 0.25)
Low Debt to Asset (< 0.2)
Value Stock (Price to Book < 3)
Strong Sharpe Ratio (> 1.2)
High 6-Month Volatility (>65%)
Smallcap (300M - 2B USD)
High Market Beta (> 0.8)
Weak Operating Margin (< 10%)
Bearish: Increased Volatility (6-month > 1-month volatility)
10 days
52.0%1 month
50.0%3 months
52.2%6 months
93.4%-
-
1.50
0.20
0.13
-0.78
20.68
-
-131.78M
1.21B
1.21B
-
-695.25
-
-
-59.51
11.58
13.04
Short-term: Bullish (SMA10D > SMA1M)
Intermediate-term: Bearish (SMA1M < SMA3M)
Long-term: Bullish (SMA6M > SMA12M)
Range10D
4.27
Range1M
6.74
Range3M
9.75
Rel. volume
0.55
Price X volume
11.39M
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
|---|---|---|---|---|---|---|---|
| Novavax Inc | NVAX | Biotechnology | 8.22 | 1.32B | 0.86% | n/a | -54.03% |
| Taysha Gene Therapies Inc | TSHA | Biotechnology | 6.4 | 1.31B | 0.00% | n/a | 53.02% |
| Capricor Therapeutics Inc | CAPR | Biotechnology | 35.27 | 1.25B | 4.16% | n/a | 45.32% |
| Array BioPharma Inc | ARRY | Biotechnology | 8.11 | 1.23B | 0.00% | 68.10 | 117.68% |
| Progenitor Inc | PGEN | Biotechnology | 4.13 | 1.21B | 4.29% | n/a | 14.69% |
| NRIX | NRIX | Biotechnology | 16.68 | 1.18B | 0.66% | n/a | 7.20% |
| AbCellera Biologics Inc | ABCL | Biotechnology | 4.15 | 1.17B | 2.47% | n/a | 6.49% |
| Pharming Group N.V. | PHAR | Biotechnology | 16.68 | 1.13B | 0.24% | n/a | 63.43% |
| Oculis Holding AG Ordinary shares | OCS | Biotechnology | 26.44 | 1.10B | -1.23% | n/a | 1.19% |
| Wave Life Sciences Ltd | WVE | Biotechnology | 7.18 | 1.09B | -1.78% | n/a | 656.70% |
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
|---|---|---|---|---|---|---|---|
| Lincoln Educational Services Corporation | LINC | Building Products & Equipment | 39.11 | 1.23B | -1.21% | 51.60 | 88.92% |
| Winnebago Industries Inc | WGO | Recreational Vehicles | 32.87 | 951.75M | 0.70% | 22.53 | 56.33% |
| Janus International Group Inc. | JBI | Building Products & Equipment | 5.44 | 790.55M | 1.30% | 11.62 | 116.21% |
| Fox Factory Holding Corp | FOXF | Recreational Vehicles | 17.7 | 737.79M | 2.31% | 42.05 | 64.69% |
| Latham Group Inc. | SWIM | Building Products & Equipment | 6.01 | 694.62M | -0.17% | 65.18 | 77.00% |
| Ennis Inc | EBF | Building Products & Equipment | 20.33 | 528.66M | -1.26% | 13.28 | 2.28% |
| Malibu Boats Inc | MBUU | Recreational Vehicles | 26.1 | 521.76M | -0.91% | n/a | 1.50% |
| MCBC Holdings Inc | MCFT | Recreational Vehicles | 23.53 | 390.77M | -0.88% | 34.27 | 26.82% |
| Camping World Holdings Inc | CWH | Recreational Vehicles | 7.48 | 337.57M | 8.41% | n/a | 3644.76% |
| ACCO Brands Corporation | ACCO | Building Products & Equipment | 3.31 | 317.09M | 1.85% | n/a | 174.23% |
| Parameter | Company | Industry | Indicator |
|---|---|---|---|
| Enterprise to EBITDA | -0.78 | 0.53 | Cheaper |
| Ent. to Revenue | 20.68 | 3,967.00 | Cheaper |
| PE Ratio | - | 41.03 | - |
| Price to Book | 1.50 | 15.55 | Cheaper |
| Dividend Yield | - | 2.20 | - |
| Std. Deviation (3M) | 52.20 | 72.80 | Lower Risk |
| Debt to Equity | 0.20 | -1.23 | Expensive |
| Debt to Assets | 0.13 | 0.25 | Cheaper |
| Market Cap | 1.21B | 3.66B | Emerging |